


























































published: 24 March 2015
doi: 10.3389/fpsyt.2015.00043
Could vagus nerve stimulation target hippocampal
hyperactivity to improve cognition in schizophrenia?
Jason Smucny 1,2,3*, AdrienneVisani 3 and Jason R.Tregellas1,2,3
1 Neuroscience Program, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2 Research Service, Denver Veterans Affairs Medical Center, Denver, CO, USA
3 Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
*Correspondence: jason.smucny@ucdenver.edu
Edited by:
Joaquim Radua, King’s College London, UK
Reviewed by:
Daniel J. Lodge, University of Texas Health Science Center in San Antonio, USA
Diego Redolar-Ripoll, Open University of Catalonia (UOC), Spain
Keywords: vagus nerve stimulation, schizophrenia patients, hippocampus, cognition, acetylcholine
Despite the fact that cognitive function
is the best predictor of functional out-
come and quality of life in schizophre-
nia (1), cognitive symptoms remain poorly
treated in the illness. A myriad of cognitive
domains are affected, including selective
and sustained attention, working mem-
ory, episodic memory, processing speed,
executive function, and social cognition
(2). Patients consequently suffer from high
unemployment rates (80%) and most are
unable to live independently (30%) (3).
Clearly, new treatments are needed.
One strategy for developing new inter-
ventions for these symptoms is to focus
on treatments that may target biologi-
cal indicators (“biomarkers”) of cogni-
tive dysfunction. Recently, our laboratory
found that resting-state hyperactivity of the
hippocampus (as examined by functional
magnetic resonance imaging) was strongly
predictive of poor cognition in schizo-
phrenia patients (4). This finding, along
with previous studies that have demon-
strated increased hippocampal blood flow
(5), blood volume (6, 7), and hyperactiv-
ity during sensory processing (8, 9) in the
disease suggests that hippocampal hyper-
activity may be a biomarker for cognitive
dysfunction in the illness (10). Loss of
inhibitory signaling in the hippocampus
is also hypothesized to play a role in sen-
sory filtering deficits in schizophrenia (11),
one of the most prominent electrophysio-
logical features of the disease. This loss is
thought to be conveyed through reduced
nicotinic (12, 13) and/or GABAergic (14)
signaling. It follows that interventions that
reduce hippocampal hyperactivity may
have therapeutic benefit in schizophrenia.
First developed in the 1980s for epilepsy,
vagus nerve stimulation (VNS) may be a
promising method for targeting hippocam-
pal hyperactivity and improving cognition
in schizophrenia. The vagus nerve (VN) is
the longest cranial nerve, extending from
the brain to the abdominal cavity. Although
the VN is traditionally thought to primarily
mediate central nervous system control of
parasympathetic function, in actuality the
VN consists of 80% afferent signals (from
external organs to the brain) and 20%
efferent signals (from the brain to organs)
(15). VNS is most commonly achieved
by surgical implantation of a stimulating,
current-carrying wire around the nerve in
the neck (16). The wire is intermittently
stimulated by a battery-operated genera-
tor that is implanted in the left chest wall.
Stimulation is directional (going to the
brain), minimizing potential side effects
from the VN’s efferent projections. Stimu-
lus parameters (e.g., stimulus intensity, fre-
quency, and duration) can be programed
by a physician to maximize efficacy. More
recently, a non-surgical method of VNS
known as transcutaneous VNS (t-VNS)
has been developed, in which the auric-
ular branch of the VN is stimulated by
electrodes placed on the outer ear (17–19).
This stimulation site is in close proximity
to an acupuncture site that may stimulate
the VN in a similar manner (20). Interest-
ingly, a number of studies have shown poor
parasympathetic regulation of autonomic
function in schizophrenia (21–26), sug-
gesting that hypoactive VN function may
contribute to disease pathophysiology.
By using VNS in combination with var-
ious functional neuroimaging techniques,
researchers have frequently examined how
VNS affects human brain activity. One
of the most consistent neurophysiological
effects of VNS is decreased hippocampal
activity, possibly through enhancement of
GABAergic signaling (27). As shown in
Table 1, decreased hippocampal activity
after VNS has been reported in over 15
studies (18, 28–44), although some oth-
ers have not reported significant effects
(45, 46). Remarkably, this effect has been
observed in epileptic patients, depressed
patients, and healthy subjects, suggesting
that VNS may decrease hippocampal activ-
ity independent of the pathological state of
the subject. Most relevant to schizophre-
nia, a recent in vivo electrophysiology study
using the methylazoxymethanol acetate
(MAM) rodent model of schizophrenia
found decreased hippocampal hyperactiv-
ity in rats after 2 weeks VNS treatment
(44). Furthermore, deep brain stimulation-
induced reduction of hippocampal hyper-
activity improves cognitive flexibility in
the MAM rat model (47), suggesting that
hyperactivity of the region may be targeted
to improve cognition in schizophrenia.
Vagus nerve stimulation also has
demonstrated pro-cognitive effects in a
number of studies. As reviewed by Vonck
et al. (48), improved cognition after
VNS has been observed in patients with
epilepsy, Alzheimer’s, and depression. Cog-
nitive domains that have shown improve-
ment include verbal recognition, atten-
tion, memory consolidation, and executive
function (48). Other studies, however, have
not shown significant effects, possibly due
to changes in stimulus or study parameters
(e.g., placebo design) (48). Indeed, studies
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Epilepsy s-VNS PET ↓ Henry et al. (28)
PET ↓ Henry et al. (29)
HC depth ↓ (epileptiform Olejniczak et al. (33)
electrodes sharp waves)
SPECT ↓ Vonck et al. (31)
SPECT ↓ Van Laere et al. (30)
SPECT ↓ Van Laere et al. (34)
SPECT ↓ Barnes et al. (35)
PET ↓ Henry et al. (36)
SPECT ↓ Vonck et al. (41)
Depression s-VNS SPECT ↓ Devous (32)
fMRI ↓ Mu et al. (37)
SPECT ↓ Zobel et al. (39)
PET n.s. Pardo et al. (45)
PET n.s. Conway et al. (46)
Healthy t-VNS fMRI ↓ Kraus et al. (40)
fMRI ↓ Kraus et al. (42)
fMRI ↓ Frangos et al. (43)
Animal (rat) s-VNS PET ↓ Dedeurwaerdere et al. (38)
in vivo electrophysiology ↓ Perez et al. (44)
fMRI, functional magnetic resonance imaging; HC, hippocampus; n.s., no significant effects; PET, positron
emission tomography; rBF, regional blood flow; s-VNS, surgicalVNS; SPECT, single-photon emission computed
tomography; t-VNS, transcutaneous (non-surgical) VNS.
that examine the effects of chronic VNS
often lack appropriate placebo controls due
to ethical issues in applying “placebo” stim-
ulation protocols to patient populations.
This concern may be addressed by stud-
ies in healthy subjects using non-invasive
t-VNS, in which placebo “stimulation” is
delivered by an electrode placed on the ear-
lobe (27). Nonetheless, the effects of non-
invasive t-VNS on cognitive performance
have yet to be well evaluated.
The effects of VNS on neurotransmit-
ter systems show important parallels with
current lines of therapeutic investigation
in schizophrenia. Ascending projections of
the VN terminate in the nucleus tractus
solitarius in the medulla, which in turn
innervates the locus coeruleus and induces
the release of norepinephrine (NE) (49,
50). Activation of adrenergic receptors in
the hippocampus can thereby reduce the
excitability of the region (51–53). In line
with a role for increased adrenergic sig-
naling in the treatment of schizophrenia,
adrenergic α2 receptor agonists such as
clonidine are currently being investigated
in early phase trials in patients. Preliminary
studies have demonstrated that activa-
tion of this receptor improves senso-
rimotor (54) and auditory gating (55)
deficits in the disease. Guanfacine, an α2A
receptor-specific agonist, also shows pro-
cognitive effects in several patient popula-
tions including schizophrenia (56–58).
A secondary effect of VNS directly rele-
vant to schizophrenia is to increase cholin-
ergic neurotransmission by NE-induced
activation of postsynaptic beta and α1
adrenergic receptors in the basal fore-
brain, leading to increased acetylcholine
(ACh) release (59). This increase may help
normalize deficits in cholinergic neuro-
transmission in the disorder driven in
large part by a significant reduction in
the expression of nicotinic ACh recep-
tors on inhibitory interneurons (11, 12,
60–63). Loss of these receptors is also
hypothesized to contribute to hippocam-
pal hyperactivity (10, 11, 62), which may
be normalized by nicotinic activation of
receptors on inhibitory interneurons (61,
64). In support of this view, nicotine, a
nicotinic receptor agonist, reduces hip-
pocampal hyperactivity observed during
smooth pursuit eye movement in schiz-
ophrenia patients (65, 66). This attempt
to “self-medicate” may help explain why
the majority of patients smoke cigarettes
(67). VNS may be a particularly effective
method of potentiating nicotinic signal-
ing as its cholinergic effects are conveyed
via increased release of ACh. Relative to
other nicotinic agonists (such as nicotine),
ACh is more quickly degraded by endoge-
nous enzymes, and is therefore less likely to
induce receptor desensitization (68).
A third mechanism by which VNS
may affect the neurobiology of schizo-
phrenia is via its ability to increase sero-
tonin release (69). Increased serotonergic
tone may in turn decrease hippocampal
hyperexcitability by potentiating GABAer-
gic signaling through activation of several
serotonin receptor subtypes, including 5-
HT-2, 3, and 4 (70–73). Activation of the
5-HT1 serotonin receptor subtype is also
associated with hippocampal neurogene-
sis and has been proposed as a potential
mechanism to restore pattern separation
(a memory-related hippocampal function)
deficits in schizophrenia (74). Further-
more, activation of 5-HT3 receptors may
relieve tonic inhibition of ACh release (75),
increasing cholinergic tone and restoring
hippocampal nicotinic signaling in the ill-
ness. How VNS specifically affects activity
at these receptor targets and their relation-
ship to cognition and hippocampal activity
are important areas for future research.
Vagus nerve stimulation, whether
administered by surgical implant or tran-
scutaneous stimulation, is a well-tolerated
procedure. Risks associated with the
surgery itself are minimal (76). The most
common side effects associated with stimu-
lation are hoarseness, dyspnea, and cough.
Most of these effects decrease with time
(77). Nonetheless, VNS may have more
significant risks specific to schizophrenia.
Compounds that non-specifically (across
all adrenergic receptor subtypes) increase
noradrenergic activity, such as ampheta-
mine, are known to induce psychosis in
normal subjects (78, 79) and worsen pos-
itive symptoms in patients (80). Indeed,
VNS itself has been associated with the
onset of psychosis in epileptic patients in
a limited number of case studies (81). It is
possible that schizophrenia patients who
are taking antipsychotic medication that
participate in a VNS study will require
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adjustment of antipsychotic doses in order
to preserve clinical efficacy. Previous stud-
ies, however, have also observed positive
correlations between VN/parasympathetic
nervous system dysfunction and positive
symptoms, suggesting that VNS may actu-
ally improve these symptoms (24, 25). As
the interactions between VNS and antipsy-
chotic efficacy in schizophrenia are entirely
unknown, studies should make closely
monitor core symptoms of the illness
associated with acute and chronic VNS
treatment.
Despite its potential to improve cogni-
tion in schizophrenia, to our knowledge no
study has yet examined the clinical or phys-
iological effects of VNS in patients with
the disease. Lack of research in this area
may be due in large part to the invasive-
ness of traditional, surgical VNS. To that
end, the advent of t-VNS provides a sim-
ple, non-invasive method for examining
the acute and chronic effects of stimulation
in schizophrenia under various stimulus
protocols. The recent discovery of hip-
pocampal hyperactivity as a biomarker for
cognitive symptoms in schizophrenia pro-
vides a useful mechanism to establish target
validation using functional neuroimaging.
In regards to VNS, the fact that numerous
studies have repeatedly demonstrated that
stimulation reduces hippocampal activity
in other patient populations suggests that
it may have the same effect in schizo-
phrenia. Furthermore, although this arti-
cle has focused on hippocampal effects,
VNS may also improve cognition through
other mechanisms, such as neurochemical
modulation of the prefrontal cortex (82–
84) and/or prefrontal–hippocampal inter-
actions (85). In summary, examination of
the potential effects of VNS for cogni-
tive symptoms in schizophrenia may be a
promising future research direction.
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